An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of ...

Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

We live in a time of hope for millions around the world, as technological advancements and research breakthroughs hold the promise of transformative treatments and cures. And with social media at our ...

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...

Single-use (SU) systems show significant promise for antibody-drug conjugate (ADC) manufacturing. However, the use of organic solvents in the ADC process raises concerns about potential leachables ...

We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...

Over the past decade, advances in drug discovery and clinical development have led to a rise in the number of approved therapies, resulting in an increasingly competitive marketplace. These evolving ...